Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)
China · Delayed Price · Currency is CNY 11.68
+0.29 (2.55%)
Apr 8, 2026, 3:04 PM CST
SHE:002399 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 5,479 | 5,259 | 5,431 | 7,097 | 6,318 |
Other Revenue | - | - | - | 61.92 | 47.33 |
| 5,479 | 5,259 | 5,431 | 7,159 | 6,365 | |
Revenue Growth (YoY) | 4.18% | -3.17% | -24.14% | 12.48% | 19.38% |
Cost of Revenue | 3,736 | 3,520 | 4,490 | 4,861 | 4,367 |
Gross Profit | 1,743 | 1,739 | 940.9 | 2,298 | 1,998 |
Selling, General & Admin | 847.8 | 1,028 | 1,192 | 975.69 | 850.68 |
Research & Development | 226.16 | - | - | 252.14 | 221.1 |
Other Operating Expenses | 33.06 | -26.66 | -34.49 | 22.73 | 20.96 |
Operating Expenses | 1,107 | 993.5 | 1,158 | 1,299 | 1,165 |
Operating Income | 635.97 | 745.82 | -217.29 | 998.55 | 833.53 |
Interest Expense | - | -141.19 | -223.22 | -235.24 | -201.63 |
Interest & Investment Income | - | 104.2 | 75.95 | 54.14 | 54.86 |
Earnings From Equity Investments | - | -141.82 | -447.95 | - | - |
Currency Exchange Gain (Loss) | - | -12.84 | 85.87 | 186.33 | -205.04 |
Other Non Operating Income (Expenses) | 11.56 | -72.08 | -30.71 | -32.55 | -46.18 |
EBT Excluding Unusual Items | 647.53 | 482.09 | -757.34 | 971.23 | 435.53 |
Impairment of Goodwill | - | - | -68.16 | - | - |
Gain (Loss) on Sale of Investments | -112.33 | 315.07 | 16.2 | -176.91 | -226.82 |
Gain (Loss) on Sale of Assets | 1.84 | - | - | -2.76 | -5.1 |
Asset Writedown | -134.81 | -55.37 | -44.52 | -0.42 | -1.1 |
Other Unusual Items | - | -15.56 | -74.52 | 38.71 | 19.75 |
Pretax Income | 402.24 | 726.23 | -928.33 | 829.85 | 222.26 |
Income Tax Expense | 59.6 | 101.31 | -126.18 | 114.82 | -11.12 |
Earnings From Continuing Operations | 342.64 | 624.92 | -802.16 | 715.04 | 233.38 |
Minority Interest in Earnings | 6.85 | 21.82 | 18.9 | 12.39 | 7.4 |
Net Income | 349.49 | 646.74 | -783.26 | 727.43 | 240.79 |
Net Income to Common | 349.49 | 646.74 | -783.26 | 727.43 | 240.79 |
Net Income Growth | -45.96% | - | - | 202.10% | -76.49% |
Shares Outstanding (Basic) | 1,467 | 1,470 | 1,478 | 1,468 | 1,467 |
Shares Outstanding (Diluted) | 1,467 | 1,470 | 1,478 | 1,468 | 1,467 |
Shares Change (YoY) | -0.18% | -0.54% | 0.67% | 0.05% | 8.42% |
EPS (Basic) | 0.24 | 0.44 | -0.53 | 0.50 | 0.16 |
EPS (Diluted) | 0.24 | 0.44 | -0.53 | 0.50 | 0.16 |
EPS Growth | -45.86% | - | - | 201.95% | -78.32% |
Free Cash Flow | 1,592 | 1,995 | -39.22 | -979.03 | -200.49 |
Free Cash Flow Per Share | 1.08 | 1.36 | -0.03 | -0.67 | -0.14 |
Dividend Per Share | - | 0.250 | - | 0.100 | 0.035 |
Dividend Growth | - | - | - | 185.71% | -76.67% |
Gross Margin | 31.81% | 33.07% | 17.32% | 32.10% | 31.39% |
Operating Margin | 11.61% | 14.18% | -4.00% | 13.95% | 13.10% |
Profit Margin | 6.38% | 12.30% | -14.42% | 10.16% | 3.78% |
Free Cash Flow Margin | 29.05% | 37.93% | -0.72% | -13.68% | -3.15% |
EBITDA | 974.94 | 1,027 | 105.61 | 1,272 | 1,103 |
EBITDA Margin | 17.79% | 19.53% | 1.94% | 17.77% | 17.34% |
D&A For EBITDA | 338.97 | 281.11 | 322.89 | 273.87 | 269.92 |
EBIT | 635.97 | 745.82 | -217.29 | 998.55 | 833.53 |
EBIT Margin | 11.61% | 14.18% | -4.00% | 13.95% | 13.10% |
Effective Tax Rate | 14.82% | 13.95% | - | 13.84% | - |
Revenue as Reported | - | - | - | 7,159 | 6,365 |
Advertising Expenses | - | - | - | 23.2 | 18.04 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.